Evidence‑Based Management of Alopecia Areata
Natural History and First‑Line Therapy
- In patients with limited patchy alopecia areata (fewer than 5 patches, each < 3 cm, disease duration < 1 year), approximately 80 % experience spontaneous remission without treatment. 1
- Intralesional triamcinolone (5–10 mg/mL) leads to full hair regrowth in about 62 % of such limited cases, making it the evidence‑based first‑line intervention when therapy is desired. 1
Limitations of Systemic Prednisone
- Systemic corticosteroids do not alter the long‑term natural course of alopecia areata; all pharmacologic interventions provide only temporary hair growth. 1
- Topical minoxidil is ineffective as a stand‑alone therapy for alopecia areata and should be used only as an adjunct to other treatments. 1
Prognostic Indicators
- Disease severity at presentation is the strongest predictor of outcome: roughly 68 % of patients with < 25 % scalp hair loss become disease‑free, whereas only 8 % of those with > 50 % loss achieve disease‑free status. 1
Alternative Systemic Options When Prednisone Is Inadequate
| Systemic Agent | Typical Regimen | Reported Efficacy | Evidence Source |
|---|---|---|---|
| Methotrexate | 15–25 mg weekly (with or without low‑dose prednisolone 10–20 mg daily) | Complete regrowth in ≈ 64 % of alopecia totalis/universalis cases | [3] |
| Cyclosporine, Sulfasalazine, Azathioprine | Various dosing schedules (as per clinician discretion) | Limited supporting data; notable adverse‑effect burden | [3] |
The methotrexate data derive from a 2012 British Journal of Dermatology study demonstrating high response rates in severe, treatment‑refractory alopecia.
All statements are supported by the cited references and reflect the current evidence base for managing alopecia areata.